TW200503729A - Treating androgen deficiency in female (ADIF)-associated conditions with SARMS - Google Patents
Treating androgen deficiency in female (ADIF)-associated conditions with SARMSInfo
- Publication number
- TW200503729A TW200503729A TW093101758A TW93101758A TW200503729A TW 200503729 A TW200503729 A TW 200503729A TW 093101758 A TW093101758 A TW 093101758A TW 93101758 A TW93101758 A TW 93101758A TW 200503729 A TW200503729 A TW 200503729A
- Authority
- TW
- Taiwan
- Prior art keywords
- female
- adif
- subject
- treating
- sarm
- Prior art date
Links
- 206010002261 Androgen deficiency Diseases 0.000 title abstract 2
- 229940083324 Selective androgen receptor modulator Drugs 0.000 abstract 4
- 239000000849 selective androgen receptor modulator Substances 0.000 abstract 4
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- -1 hydrate Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44130803P | 2003-01-22 | 2003-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200503729A true TW200503729A (en) | 2005-02-01 |
Family
ID=32771915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093101758A TW200503729A (en) | 2003-01-22 | 2004-01-27 | Treating androgen deficiency in female (ADIF)-associated conditions with SARMS |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050032750A1 (https=) |
| EP (1) | EP1594490A4 (https=) |
| JP (1) | JP2006516286A (https=) |
| CN (1) | CN1771031A (https=) |
| AU (1) | AU2004206909A1 (https=) |
| CA (1) | CA2514024A1 (https=) |
| TW (1) | TW200503729A (https=) |
| WO (1) | WO2004064747A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
| US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
| WO2004035739A2 (en) * | 2002-10-16 | 2004-04-29 | Gtx, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
| US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
| WO2005037201A2 (en) * | 2003-10-14 | 2005-04-28 | Gtx, Inc. | Treating bone-related disorders with selective androgen receptor modulators |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| WO2007045027A1 (en) | 2005-10-19 | 2007-04-26 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| KR100785038B1 (ko) * | 2006-04-17 | 2007-12-12 | 삼성전자주식회사 | 비정질 ＺｎＯ계 ＴＦＴ |
| MX2009000385A (es) * | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Acil-anilidas sustituidas y metodos de uso de las mismas. |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| ES2581765T3 (es) * | 2006-08-24 | 2016-09-07 | University Of Tennessee Research Foundation | Acilanilidas sustituidas y métodos de uso de las mismas |
| US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| US8791158B2 (en) | 2010-01-11 | 2014-07-29 | Gtx, Inc. | Methods of treating meibomian gland dysfunction |
| FR2982261B1 (fr) | 2011-11-04 | 2014-06-13 | Galderma Res & Dev | Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| LT2872482T (lt) * | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| CA2965372C (en) | 2014-10-22 | 2023-09-05 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| JP2018534291A (ja) | 2015-10-22 | 2018-11-22 | ハバフ セラピューティクス ピーティーワイ エルティーディー | マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法 |
| CN106405064B (zh) * | 2016-08-30 | 2018-10-26 | 嘉兴行健生物科技有限公司 | 一种40岁以上女性骨转换率的评估方法 |
| AU2020287392A1 (en) | 2019-06-03 | 2021-12-23 | Havah Therapeutics Pty Ltd | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use |
| US11701332B2 (en) | 2020-11-18 | 2023-07-18 | Bryce Nicholas Day | Methods and compositions for treating female sexual interest and arousal disorder |
| US20230172897A1 (en) * | 2021-12-02 | 2023-06-08 | Veru, Inc. | Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents |
| WO2025102293A1 (zh) * | 2023-11-16 | 2025-05-22 | 北京脑科学与类脑研究所 | 神经活性雄激素受体调节剂及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8617653D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| NZ251047A (en) * | 1992-04-10 | 1996-09-25 | Pfizer | Acylaminoindole derivatives and medicaments |
| DE60137728D1 (de) * | 2000-08-24 | 2009-04-02 | Univ Tennessee Res Foundation | Selektive Modulatoren des Androgenrezeptors und Methoden zu deren Verwendung |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| KR20040104463A (ko) * | 2002-02-28 | 2004-12-10 | 유니버시티 오브 테네시 리서치 파운데이션 | 비가역적 선택적 안드로겐 수용체 모듈레이터 및 이를사용하는 방법 |
| AU2003216153B2 (en) * | 2002-02-28 | 2008-01-24 | The University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
| JP2005529952A (ja) * | 2002-06-17 | 2005-10-06 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | Ｎ架橋選択的アンドロゲン受容体修飾物質及びその使用方法 |
| CA2502209A1 (en) * | 2002-10-15 | 2004-04-29 | University Of Tennessee Research Foundation | Methylene-bridged selective androgen receptor modulators and methods of use thereof |
-
2004
- 2004-01-20 AU AU2004206909A patent/AU2004206909A1/en not_active Abandoned
- 2004-01-20 WO PCT/US2004/001359 patent/WO2004064747A2/en not_active Ceased
- 2004-01-20 US US10/759,538 patent/US20050032750A1/en not_active Abandoned
- 2004-01-20 CA CA002514024A patent/CA2514024A1/en not_active Abandoned
- 2004-01-20 JP JP2006501034A patent/JP2006516286A/ja active Pending
- 2004-01-20 EP EP04703606A patent/EP1594490A4/en not_active Withdrawn
- 2004-01-20 CN CNA2004800077667A patent/CN1771031A/zh active Pending
- 2004-01-27 TW TW093101758A patent/TW200503729A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1771031A (zh) | 2006-05-10 |
| WO2004064747A3 (en) | 2005-01-27 |
| EP1594490A4 (en) | 2006-03-22 |
| EP1594490A2 (en) | 2005-11-16 |
| CA2514024A1 (en) | 2004-08-05 |
| US20050032750A1 (en) | 2005-02-10 |
| WO2004064747A2 (en) | 2004-08-05 |
| JP2006516286A (ja) | 2006-06-29 |
| AU2004206909A2 (en) | 2004-08-05 |
| AU2004206909A1 (en) | 2004-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200503729A (en) | Treating androgen deficiency in female (ADIF)-associated conditions with SARMS | |
| CA2538095A1 (en) | Selective androgen receptor modulators and methods of use thereof | |
| TW200407280A (en) | N-bridged selective androgen receptor modulators and methods of use thereof | |
| WO2004035737A3 (en) | Heterocyclic selective androgen receptor modulators and methods of use thereof | |
| WO2004035738A3 (en) | Methylene-bridged selective androgen receptor modulators and methods of use thereof | |
| EP1487458A4 (en) | MULTI-SUBSTITUTED ANDROGEN SELECTIVE RECEPTOR MODULATORS AND METHODS AND USES THEREOF | |
| WO2003074449A3 (en) | Multi-substitued selective androgen receptor modulators and methods of use thereof | |
| WO2005113565A3 (en) | Metabolites of selective androgen receptor modulators and methods of use thereof | |
| TW200502250A (en) | Treating androgen decline in aging male (ADAM)-associated conditions with SARMS | |
| WO2004062612A3 (en) | Large-scale synthesis of selective androgen receptor modulators | |
| WO2003074473A3 (en) | Irreversible selective androgen receptor modulators and methods of use thereof | |
| PL1902026T3 (pl) | Pochodne tetrahydrokarbazolu użyteczne jako modulatory receptora androgenowego (SARM) | |
| PL1891038T3 (pl) | Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego | |
| MX356271B (es) | Composiciones de alquilglicósido para administracion de farmacos. | |
| WO2009140448A8 (en) | Tetrahydrocyclopenta[b]indole androgen receptor modulators | |
| MA34046B1 (fr) | Ligands sigma pour potentialiser l'effet analgésique d'opioïdes et d'opiacés dans une douleur post-opératoire et atténuer la dépendance à ceux-ci | |
| WO2005037201A3 (en) | Treating bone-related disorders with selective androgen receptor modulators | |
| WO2007081696A3 (en) | Treating androgen decline in aging male (adam)-associated conditions with sarms | |
| MX2007002606A (es) | Uso de un modulador del receptor selectivo a estrogeno para la elaboracion de una preparacion farmaceutica para uso en un metodo para el tratamiento o prevencion de la deficiencia de androgenos. | |
| TW200716662A (en) | Process for making fluorinated 4-azasteroid derivatives | |
| TW200512204A (en) | A method of treating breast cancer with androgen receptor antagonists | |
| WO2005116027A3 (en) | Indazole and indolone derivatives and their use as pharmaceuticals | |
| EA200401123A1 (ru) | Галогенацетамидные и азидзамещённые соединения и способы их применения |